Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer Cycles
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00542126|
Recruitment Status : Unknown
Verified September 2007 by Shaare Zedek Medical Center.
Recruitment status was: Not yet recruiting
First Posted : October 10, 2007
Last Update Posted : October 10, 2007
Supraphysiological hormonal stimulation enables collecting many oocytes in an In-Vitro Fertilization treatment, but may have a negative effect on uterine function and contribute the fact that the majority of preembryos placed in the uterus fail to implant.
Several medical agents were shown to be beneficial when given in the luteal phase of an IVF cycle, but the optimal regimen has not been yet determined. In 2006, a European group reported that addition of GnRH analog (Decapeptyl) as luteal support in IVF cycle significantly improved pregnancy and delivery rates. It is not known whether this positive effect influences the corpus luteum, embryo or the uterus. The researchers sought to evaluate the effect of GnRH administration as luteal support in frozen-thaws IVF cycle.
|Condition or disease||Intervention/treatment||Phase|
|Pregnancy Rate||Drug: Decapeptyl 0.1 mg after embryo transfer||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||December 2007|
|Estimated Study Completion Date :||September 2009|
Active Comparator: 1
GnRH analog administration following embryo transfer
Drug: Decapeptyl 0.1 mg after embryo transfer
Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
|No Intervention: 2|
- pregnancy and delivery rates
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00542126
|Contact: Avi Tsafrir, MDfirstname.lastname@example.org|
|Contact: Ehud Margalioth, MD||ehudMD@scmz.org.il|
|IVF unit, Shaare-Zedek Medical Center||Recruiting|
|Jerusalem, Israel, 91031|
|Contact: Avi Tsafrir, MD 972-508573805 email@example.com|
|Principal Investigator: Avi Tsafrir, MD|
|Principal Investigator:||Avi Tsafrir, MD||Shaare-Zedek Medical Center, Jerusalem, Israel|